PML-IRIS in a patient treated with brentuximab.
von Geldern G, Pardo CA, Calabresi PA, Newsome SD.
Neurology · brief-report; journal article; case reports · DOI 10.1212/wnl.0b013e3182749f17 PUBLICATION REGISTRY
Go to research.
Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.
Publikationer som ChEBI hänvisar till för pralatrexate. Visa hela publikationsregistret
A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.
Publications in the selection
25 hitsLack of expression of MTAP in uncommon T-cell lymphomas.
Bertino JR, Lubin M, Johnson-Farley N, Chan WC, Goodell L, Bhagavathi S.
Clin Lymphoma Myeloma Leuk · journal article · DOI 10.1016/j.clml.2012.07.001Antifolates in cancer therapy: structure, activity and mechanisms of drug resistance.
Gonen N, Assaraf YG.
Drug Resist Updat · review; journal article · DOI 10.1016/j.drup.2012.07.002Safety and efficacy of pralatrexate in the management of relapsed or refractory peripheral T-cell lymphoma.
Rodd AL, Ververis K, Karagiannis TC.
Clin Med Insights Oncol · review-article; journal article · DOI 10.4137/cmo.s8536Anaplastic large cell lymphoma, ALK-negative.
Ferreri AJ, Govi S, Pileri SA, Savage KJ.
Crit Rev Oncol Hematol · review; journal article · DOI 10.1016/j.critrevonc.2012.06.004Pralatrexate (Folotyn).
Abramovits W, Oquendo M, Granowski P, Gupta A, Cather J.
Skinmed · journal articleRandomized phase 2b study of pralatrexate versus erlotinib in patients with stage IIIB/IV non-small-cell lung cancer (NSCLC) after failure of prior platinum-based therapy.
Kelly K, Azzoli CG, Zatloukal P, Albert I, Jiang PY, Bodkin D, Pereira JR, Juhász E, Iannotti NO, Weems G, Koutsoukos T, Patel JD.
J Thorac Oncol · clinical trial, phase ii; comparative study; research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1097/jto.0b013e31824cc66cClinical development of new formulations of cytotoxics in solid tumors.
Azim HA, Awada A.
Curr Opin Oncol · research support, non-u.s. gov't; review; journal article · DOI 10.1097/cco.0b013e328351fb29Pralatrexate is an effective treatment for relapsed or refractory transformed mycosis fungoides: a subgroup efficacy analysis from the PROPEL study.
Foss F, Horwitz SM, Coiffier B, Bartlett N, Popplewell L, Pro B, Pinter-Brown LC, Shustov A, Furman RR, Haioun C, Koutsoukos T, O'Connor OA.
Clin Lymphoma Myeloma Leuk · clinical trial, phase ii; research support, non-u.s. gov't; multicenter study; journal article · DOI 10.1016/j.clml.2012.01.010Management of cutaneous T cell lymphoma: new and emerging targets and treatment options.
Li JY, Horwitz S, Moskowitz A, Myskowski PL, Pulitzer M, Querfeld C.
Cancer Manag Res · review-article; journal article · DOI 10.2147/cmar.s9660Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma.
Horwitz SM, Kim YH, Foss F, Zain JM, Myskowski PL, Lechowicz MJ, Fisher DC, Shustov AR, Bartlett NL, Delioukina ML, Koutsoukos T, Saunders ME, O'Connor OA, Duvic M.
Blood · clinical trial, phase ii; comparative study; research support, non-u.s. gov't; clinical trial, phase i; journal article · DOI 10.1182/blood-2011-11-390211Pralatrexate with vitamin supplementation in patients with previously treated, advanced non-small cell lung cancer: safety and efficacy in a phase 1 trial.
Azzoli CG, Patel JD, Krug LM, Miller V, James L, Kris MG, Ginsberg M, Subzwari S, Tyson L, Dunne M, May J, Huntington M, Saunders M, Sirotnak FM.
J Thorac Oncol · research support, non-u.s. gov't; multicenter study; clinical trial, phase i; journal article · DOI 10.1097/jto.0b013e31822adb19Peripheral T-cell lymphomas: diagnosis and treatment options. Proceedings from a live roundtable, August 17, 2011, Kauai, Hawaii.
Cheson BD, Horwitz SM, Weisenburger DD.
Clin Adv Hematol Oncol · conference proceedings; research support, non-u.s. gov'tCritical appraisal of pralatrexate in the management of difficult-to-treat peripheral T cell lymphoma.
Casanova M, Medina-Pérez A, Moreno-Beltran M, Mata-Vazquez M, Rueda A.
Ther Clin Risk Manag · review-article; journal article · DOI 10.2147/tcrm.s22834Targeted molecular therapy in peripheral T-cell lymphomas.
Roncolato F, Gazzola A, Zinzani PL, Pileri SA, Piccaluga PP.
Expert Rev Hematol · research support, non-u.s. gov't; review; journal article · DOI 10.1586/ehm.11.55Pralatrexate: a novel synthetic antifolate for relapsed or refractory peripheral T-cell lymphoma and other potential uses.
Hui J, Przespo E, Elefante A.
J Oncol Pharm Pract · review; journal article · DOI 10.1177/1078155211420605Evaluation of the pharmacokinetics, preclinical and clinical efficacy of pralatrexate for the treatment of T-cell lymphoma.
Foss FM.
Expert Opin Drug Metab Toxicol · review; journal article · DOI 10.1517/17425255.2011.595404New drug therapies in peripheral T-cell lymphoma.
Howman RA, Prince HM.
Expert Rev Anticancer Ther · review; journal article · DOI 10.1586/era.11.4Therapeutic advances in cutaneous T-cell lymphoma.
Akilov OE, Geskin L.
Skin Therapy Lett · research-article; review; journal articlePralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study.
O'Connor OA, Pro B, Pinter-Brown L, Bartlett N, Popplewell L, Coiffier B, Lechowicz MJ, Savage KJ, Shustov AR, Gisselbrecht C, Jacobsen E, Zinzani PL, Furman R, Goy A, Haioun C, Crump M, Zain JM, Hsi E, Boyd A, Horwitz S.
J Clin Oncol · clinical trial, phase ii; research-article; multicenter study; journal article · DOI 10.1200/jco.2010.29.9024Single agent and combination studies of pralatrexate and molecular correlates of sensitivity.
Serova M, Bieche I, Sablin MP, Pronk GJ, Vidaud M, Cvitkovic E, Faivre S, Raymond E.
Br J Cancer · research support, non-u.s. gov't; research-article; journal article · DOI 10.1038/sj.bjc.6606063Folotyn (pralatrexate injection) for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma: U.S. Food and Drug Administration drug approval summary.
Malik SM, Liu K, Qiang X, Sridhara R, Tang S, McGuinn WD, Verbois SL, Marathe A, Williams GM, Bullock J, Tornoe C, Lin SC, Ocheltree T, Vialpando M, Kacuba A, Justice R, Pazdur R.
Clin Cancer Res · clinical trial, phase ii; multicenter study; review; journal article · DOI 10.1158/1078-0432.ccr-10-1214Peripheral T-cell lymphoma--not otherwise specified.
Savage KJ, Ferreri AJ, Zinzani PL, Pileri SA.
Crit Rev Oncol Hematol · review; journal article · DOI 10.1016/j.critrevonc.2010.07.007Pralatrexate (Folotyn) for peripheral T-cell lymphoma.
Författaruppgift saknas
Med Lett Drugs Ther · journal articlePrimary cutaneous and systemic anaplastic large cell lymphoma: clinicopathologic aspects and therapeutic options.
Querfeld C, Khan I, Mahon B, Nelson BP, Rosen ST, Evens AM.
Oncology (Williston Park) · review; journal article